Trial Profile

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis

Status: Recruiting

Phase of Trial: Phase III/IV

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary) ; Adalimumab; Etanercept
Indications Rheumatoid arthritis
Focus Adverse reactions
Acronyms RA-BRANCH
Sponsors Eli Lilly and Company

Most Recent Events

28 May 2025 Planned End Date changed from 1 Apr 2026 to 1 May 2025.
28 May 2025 Planned primary completion date changed from 1 Apr 2026 to 1 May 2025.
22 Jan 2025 Planned End Date changed from 1 Feb 2026 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com